US pharma company Gilead International aims to introduce Vosevi, a Hepatitis C drug, to Egypt within the next two months, said Amgad Talaat, general manager of EvaPharma, Gilead’s agent in Africa. Talaat said the drug, which will target patients who have not responded to available treatments such as Sovaldi, is in the process of being registered and approved by the Health Ministry to be available in May.

Tags: